The estimated Net Worth of Lifesciences Iii, L.P.Claru... is at least $10.6 Milion dollars as of 29 September 2020. Lifesciences Claru owns over 250,000 units of Graybug Vision stock worth over $10,617,173 and over the last 4 years Lifesciences sold GRAY stock worth over $0.
Sign up
Lifesciences Claru GRAY stock SEC Form 4 insiders trading
Lifesciences has made over 1 trades of the Graybug Vision stock since 2020, according to the Form 4 filled with the SEC. Most recently Lifesciences bought 250,000 units of GRAY stock worth $4,000,000 on 29 September 2020.
The largest trade Lifesciences's ever made was buying 250,000 units of Graybug Vision stock on 29 September 2020 worth over $4,000,000. On average, Lifesciences trades about 250,000 units every 0 days since 2020. As of 29 September 2020 Lifesciences still owns at least 1,930,395 units of Graybug Vision stock.
You can see the complete history of Lifesciences Claru stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Graybug Vision
Over the last 4 years, insiders at Graybug Vision have traded over $0 worth of Graybug Vision stock and bought 2,393,750 units worth $38,300,000 . The most active insiders traders include Advisors Llc Orbi Med Capit..., James E Deerfield Mgmt Hif,... oraz Frederic Guerard. On average, Graybug Vision executives and independent directors trade stock every 35 days with the average trade being worth of $720,841. The most recent stock trade was executed by Robert S Breuil on 14 March 2023, trading 5,000 units of GRAY stock currently worth $27,500.
What does Graybug Vision do?
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.
What does Graybug Vision's logo look like?
Complete history of Lifesciences Claru stock trades at Graybug Vision
Graybug Vision executives and stock owners
Graybug Vision executives and other stock owners filed with the SEC include:
-
Dr. Frederic Guerard Pharm.D.,
Pres, CEO, Sec. & Director -
Daniel Salain,
Chief Technical Operations Officer -
Dr. Parisa Zamiri M.D., Ph.D.,
Chief Medical Officer -
Robert S. Breuil,
Chief Financial Officer -
Dr. Gerald D. Cagle Ph.D.,
Sr. Advisor, Head of Bus. Devel. & Director -
Dr. Peter J. McDonnell M.D.,
Co-Founder -
Ali Kakavand,
VP & Head of Program Management -
Ming Yang,
Sr. VP of R&D -
Dr. Peter A. Campochiaro M.D.,
Co-Founder -
Dr. Ward M. Peterson Ph.D.,
Sr. VP of Preclinical Devel. -
Bettina Maunz,
Chief People Officer & Head of Communications -
Dr. Peter J. McDonnell,
Co-Founder -
Dr. Peter A. Campochiaro,
Co-Founder -
Dr. Gerald D. Cagle,
Sr. Advisor, Head of Bus. Devel. & Director -
Christina Ackermann,
Director -
Eric Bjerkholt,
Director -
Robert S Breuil,
Chief Financial Officer -
Julia Marie Eastland,
Director -
Gerald D. Cagle,
Director -
Daniel Salain,
CTOO -
Hansoo Michael Keyoung,
Director -
Advisors Llc Orbi Med Capit...,
-
Christy L Shaffer,
Director -
Lifesciences Iii, L.P.Claru...,
-
James E Deerfield Mgmt Hif,...,
-
Frederic Guerard,
Chief Executive Officer -
Parisa Zamiri,
Chief Medical Officer -
Dirk Sauer,
Director